INVIVYD INC

Investor insights: Invivyd’s CFO buys 102k shares amid a 26% weekly rally, while executives execute Rule 10b5‑1 sells—signaling confidence in the company’s antibody pipeline.

Invivyd insider buy of 1.125M shares shows senior leadership confidence in Phase III NVD200, boosting investor outlook and market‑access prospects.

Invivyd insider buys and tax‑cover sells show leadership’s confidence, with Phase 3 data poised to shift a speculative stock toward real revenue.

Invivyd’s CFO and C‑suite buy 2.8 M zero‑cost options, signaling confidence in a rising share price amid volatility and a hopeful 2026 outlook for its NVD200 antibody pipeline.